IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer Recurrent Interventions: Drug: IN10018; Drug: Placebo of IN10018; Drug: Pegylated Liposomal Doxorubicin Sponsor: InxMed (Shanghai) Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials